Pharmacokinetics and pharmacodynamics of oral mecamylamine - Development of a nicotinic acetylcholine receptor antagonist cognitive challenge test using modelling and simulation

Ricardo Alvarez-Jimenez, Anne Catrien Baakman, Jasper Stevens, Sebastiaan C. Goulooze, Ellen P. Hart, Robert Rissmann, Joop M.A. Van Gerven, Geert Jan Groeneveld

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

A pharmacologic challenge model with a nicotinic antagonist could be an important tool not only to understand the complex role of the nicotinic cholinergic system in cognition, but also to develop novel compounds acting on the nicotinic acetylcholine receptor. The objective was to develop a pharmacokinetic-pharmacodynamic (PKPD) model using nonlinear mixed effects (NLME) methods to quantitate the pharmacokinetics of three oral mecamylamine doses (10, 20 and 30 mg) and correlate the plasma concentrations to the pharmacodynamic effects on a cognitive and neurophysiologic battery of tests in healthy subjects. A one-compartment linear kinetic model best described the plasma concentrations of mecamylamine. Mecamylamine's estimated clearance was 0.28 ± 0.015 L min-1. The peripheral volume of distribution (291 ± 5.15 L) was directly related to total body weight. Mecamylamine impaired the accuracy and increased the reaction time in tests evaluating short term working memory with a steep increase in the concentration-effect relationship at plasma concentrations below 100 μg L-1. On the other hand, mecamylamine induced a decrease in performance of tests evaluating visual and fine motor coordination at higher plasma concentrations (EC50 97 μg L-1). Systolic and diastolic blood pressure decreased exponentially after a plasma mecamylamine concentration of 80 μg L-1, a known effect previously poorly studied in healthy subjects. The developed mecamylamine PKPD model was used to quantify the effects of nicotinic blockade in a set of neurophysiological tests in humans with the goal to provide insight into the physiology and pharmacology of the nicotinic system in humans and the possibility to optimize future trials that use mecamylamine as a pharmacological challenge.

LanguageEnglish
Pages192-203
Number of pages12
JournalJournal of Psychopharmacology
Volume31
Issue number2
DOIs
Publication statusPublished - 1 Feb 2017

Cite this

Alvarez-Jimenez, Ricardo ; Baakman, Anne Catrien ; Stevens, Jasper ; Goulooze, Sebastiaan C. ; Hart, Ellen P. ; Rissmann, Robert ; Van Gerven, Joop M.A. ; Groeneveld, Geert Jan. / Pharmacokinetics and pharmacodynamics of oral mecamylamine - Development of a nicotinic acetylcholine receptor antagonist cognitive challenge test using modelling and simulation. In: Journal of Psychopharmacology. 2017 ; Vol. 31, No. 2. pp. 192-203.
@article{94533d9b44f445bf8cbbc59a5d10dfa7,
title = "Pharmacokinetics and pharmacodynamics of oral mecamylamine - Development of a nicotinic acetylcholine receptor antagonist cognitive challenge test using modelling and simulation",
abstract = "A pharmacologic challenge model with a nicotinic antagonist could be an important tool not only to understand the complex role of the nicotinic cholinergic system in cognition, but also to develop novel compounds acting on the nicotinic acetylcholine receptor. The objective was to develop a pharmacokinetic-pharmacodynamic (PKPD) model using nonlinear mixed effects (NLME) methods to quantitate the pharmacokinetics of three oral mecamylamine doses (10, 20 and 30 mg) and correlate the plasma concentrations to the pharmacodynamic effects on a cognitive and neurophysiologic battery of tests in healthy subjects. A one-compartment linear kinetic model best described the plasma concentrations of mecamylamine. Mecamylamine's estimated clearance was 0.28 ± 0.015 L min-1. The peripheral volume of distribution (291 ± 5.15 L) was directly related to total body weight. Mecamylamine impaired the accuracy and increased the reaction time in tests evaluating short term working memory with a steep increase in the concentration-effect relationship at plasma concentrations below 100 μg L-1. On the other hand, mecamylamine induced a decrease in performance of tests evaluating visual and fine motor coordination at higher plasma concentrations (EC50 97 μg L-1). Systolic and diastolic blood pressure decreased exponentially after a plasma mecamylamine concentration of 80 μg L-1, a known effect previously poorly studied in healthy subjects. The developed mecamylamine PKPD model was used to quantify the effects of nicotinic blockade in a set of neurophysiological tests in humans with the goal to provide insight into the physiology and pharmacology of the nicotinic system in humans and the possibility to optimize future trials that use mecamylamine as a pharmacological challenge.",
keywords = "cognitive challenge test, healthy subjects, Mecamylamine, NONMEM, pharmacokinetic-pharmacodynamic modelling",
author = "Ricardo Alvarez-Jimenez and Baakman, {Anne Catrien} and Jasper Stevens and Goulooze, {Sebastiaan C.} and Hart, {Ellen P.} and Robert Rissmann and {Van Gerven}, {Joop M.A.} and Groeneveld, {Geert Jan}",
year = "2017",
month = "2",
day = "1",
doi = "10.1177/0269881116681417",
language = "English",
volume = "31",
pages = "192--203",
journal = "Journal of Psychopharmacology",
issn = "0269-8811",
publisher = "SAGE Publications Ltd",
number = "2",

}

Pharmacokinetics and pharmacodynamics of oral mecamylamine - Development of a nicotinic acetylcholine receptor antagonist cognitive challenge test using modelling and simulation. / Alvarez-Jimenez, Ricardo; Baakman, Anne Catrien; Stevens, Jasper; Goulooze, Sebastiaan C.; Hart, Ellen P.; Rissmann, Robert; Van Gerven, Joop M.A.; Groeneveld, Geert Jan.

In: Journal of Psychopharmacology, Vol. 31, No. 2, 01.02.2017, p. 192-203.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Pharmacokinetics and pharmacodynamics of oral mecamylamine - Development of a nicotinic acetylcholine receptor antagonist cognitive challenge test using modelling and simulation

AU - Alvarez-Jimenez, Ricardo

AU - Baakman, Anne Catrien

AU - Stevens, Jasper

AU - Goulooze, Sebastiaan C.

AU - Hart, Ellen P.

AU - Rissmann, Robert

AU - Van Gerven, Joop M.A.

AU - Groeneveld, Geert Jan

PY - 2017/2/1

Y1 - 2017/2/1

N2 - A pharmacologic challenge model with a nicotinic antagonist could be an important tool not only to understand the complex role of the nicotinic cholinergic system in cognition, but also to develop novel compounds acting on the nicotinic acetylcholine receptor. The objective was to develop a pharmacokinetic-pharmacodynamic (PKPD) model using nonlinear mixed effects (NLME) methods to quantitate the pharmacokinetics of three oral mecamylamine doses (10, 20 and 30 mg) and correlate the plasma concentrations to the pharmacodynamic effects on a cognitive and neurophysiologic battery of tests in healthy subjects. A one-compartment linear kinetic model best described the plasma concentrations of mecamylamine. Mecamylamine's estimated clearance was 0.28 ± 0.015 L min-1. The peripheral volume of distribution (291 ± 5.15 L) was directly related to total body weight. Mecamylamine impaired the accuracy and increased the reaction time in tests evaluating short term working memory with a steep increase in the concentration-effect relationship at plasma concentrations below 100 μg L-1. On the other hand, mecamylamine induced a decrease in performance of tests evaluating visual and fine motor coordination at higher plasma concentrations (EC50 97 μg L-1). Systolic and diastolic blood pressure decreased exponentially after a plasma mecamylamine concentration of 80 μg L-1, a known effect previously poorly studied in healthy subjects. The developed mecamylamine PKPD model was used to quantify the effects of nicotinic blockade in a set of neurophysiological tests in humans with the goal to provide insight into the physiology and pharmacology of the nicotinic system in humans and the possibility to optimize future trials that use mecamylamine as a pharmacological challenge.

AB - A pharmacologic challenge model with a nicotinic antagonist could be an important tool not only to understand the complex role of the nicotinic cholinergic system in cognition, but also to develop novel compounds acting on the nicotinic acetylcholine receptor. The objective was to develop a pharmacokinetic-pharmacodynamic (PKPD) model using nonlinear mixed effects (NLME) methods to quantitate the pharmacokinetics of three oral mecamylamine doses (10, 20 and 30 mg) and correlate the plasma concentrations to the pharmacodynamic effects on a cognitive and neurophysiologic battery of tests in healthy subjects. A one-compartment linear kinetic model best described the plasma concentrations of mecamylamine. Mecamylamine's estimated clearance was 0.28 ± 0.015 L min-1. The peripheral volume of distribution (291 ± 5.15 L) was directly related to total body weight. Mecamylamine impaired the accuracy and increased the reaction time in tests evaluating short term working memory with a steep increase in the concentration-effect relationship at plasma concentrations below 100 μg L-1. On the other hand, mecamylamine induced a decrease in performance of tests evaluating visual and fine motor coordination at higher plasma concentrations (EC50 97 μg L-1). Systolic and diastolic blood pressure decreased exponentially after a plasma mecamylamine concentration of 80 μg L-1, a known effect previously poorly studied in healthy subjects. The developed mecamylamine PKPD model was used to quantify the effects of nicotinic blockade in a set of neurophysiological tests in humans with the goal to provide insight into the physiology and pharmacology of the nicotinic system in humans and the possibility to optimize future trials that use mecamylamine as a pharmacological challenge.

KW - cognitive challenge test

KW - healthy subjects

KW - Mecamylamine

KW - NONMEM

KW - pharmacokinetic-pharmacodynamic modelling

UR - http://www.scopus.com/inward/record.url?scp=85011930969&partnerID=8YFLogxK

U2 - 10.1177/0269881116681417

DO - 10.1177/0269881116681417

M3 - Article

VL - 31

SP - 192

EP - 203

JO - Journal of Psychopharmacology

T2 - Journal of Psychopharmacology

JF - Journal of Psychopharmacology

SN - 0269-8811

IS - 2

ER -